Skip to main content

Advertisement

Table 2 Blood biochemistry and arterial stiffness before and after saxagliptin treatment

From: The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial

  Visit 1 Visit 2 Visit 3 p-value*
Blood biochemistries
Glucose
Placebo 114.8 ± 5.3 113.8 ± 5.5 112.1 ± 4.8 0.233
Saxagliptin 125.9 ± 7.8 113.5 ± 7.6 117.1 ± 5.8
BUN
Placebo 14.0 ± 0.9 13.0 ± 0.8 13.7 ± 0.7 0.205
Saxagliptin 13.1 ± 0.7 13.9 ± 0.8 13.5 ± 0.8
Serum creatinine
Placebo 1.2 ± 0.3 1.0 ± 0.1 0.9 ± 0.1 0.118
Saxagliptin 0.9 ± 0.0 0.9 ± 0.0 0.8 ± 0.0
eGFR
Placebo 93.7 ± 3.6 93.0 ± 3.8 92.7 ± 3.9 0.357
Saxagliptin 98.3 ± 3.1 93.4 ± 2.7 26.9 ± 2.9
Cholesterol
Placebo 174.5 ± 9.9 166.0 ± 7.1 164.3 ± 7.0 0.299
Saxagliptin 170.1 ± 8.1 168.8 ± 6.6 171.8 ± 8.5
Triglycerides
Placebo 106.2 ± 7.3 112.0 ± 10.0 107.8 ± 7.3 0.972
Saxagliptin 122.3 ± 13.7 126.5 ± 13.1 121.7 ± 11.3
LDL/HDL
Placebo 2.3 ± 0.2 2.1 ± 0.2 2.1 ± 0.2 0.160
Saxagliptin 1.8 ± 0.1 1.8 ± 0.1 1.8 ± 0.2
HbA1C
Placebo 6.6 ± 0.1 6.6 ± 0.1 6.5 ± 0.1 0.164
Saxagliptin 7.0 ± 0.2 6.8 ± 0.2 6.7 ± 0.2
C-reactive protein
Placebo 2.4 ± 0.6 2.9 ± 0.8 2.9 ± 0.7 0.156
Saxagliptin 2.8 ± 0.5 2.7 ± 0.4 2.4 ± 0.4
IL-6
Placebo 2.7 ± 0.6 4.0 ± 0.7 4.3 ± 0.9 0.629
Saxagliptin 3.1 ± 0.4 3.9 ± 0.7 3.8 ± 0.8
TNF-α
Placebo 3.1 ± 0.9 2.8 ± 1.1 1.6 ± 0.2 0.213
Saxagliptin 1.7 ± 0.2 1.9 ± 0.2 2.9 ± 1.3
Leptin
Placebo 14.1 ± 2.1 13.1 ± 1.8 13.8 ± 2.4 0.409
Saxagliptin 19.4 ± 3.7 17.4 ± 2.8 20.4 ± 3.5
Adiponectin
Placebo 4.6 ± 0.6 4.9 ± 0.6 5.5 ± 0.6 0.010*
Saxagliptin 4.2 ± 0.6 4.9 ± 0.7 4.0 ± 0.5
GLP1 (ELISA)
Placebo 271.9 ± 67.2 241.1 ± 63.8 295.7 ± 78.5 0.400
Saxagliptin 245.9 ± 59.0 245.3 ± 55.5 234.0 ± 58.7
SDF-1ɑ (ELISA)
Placebo − 1.84 ± 0.27 − 1.83 ± 0.27 − 1.80 ± 0.27 0.245
Saxagliptin − 1.99 ± 0.27 − 1.61 ± 0.27 − 1.87 ± 0.25
Arterial stiffness
Diastolic blood pressure (radial)
Placebo 82.7 ± 1.8 82.4 ± 2.3 82.0 ± 2.0 0.3723
Saxagliptin 84.9 ± 1.5 84.3 ± 1.2 81.9 ± 1.1
Diastolic blood pressure (arterial)
Placebo 84.4 ± 1.4 83.4 ± 2.2 83.1 ± 2.0 0.568
Saxagliptin 85.4 ± 1.5 84.6 ± 1.1 82.8 ± 1.1
Systolic blood pressure (radial)
Placebo 131.8 ± 3.6 126.0 ± 4.3 134.0 ± 3.5 0.009*
Saxagliptin 132.7 ± 2.5 133.1 ± 1.8 127.7 ± 2.3
Systolic blood pressure (arterial)
Placebo 118.7 ± 3.0 130.0 ± 7.9 121.2 ± 3.3 0.061
Saxagliptin 121.8 ± 1.7 117.5 ± 2.2 122.6 ± 2.6
Augmentation index-75
Placebo 18.4 ± 2.4 26.0 ± 3.9 23.3 ± 2.3 0.037*
Saxagliptin 24.1 ± 2.1 22.5 ± 2.0 23.1 ± 2.1
  1. * p-values are for the treatment group by visit interaction in the mixed model. This indicates whether the treatment groups had different slopes over time